This is what the news should sound like. The biggest stories of our time, told by the best journalists in the world. Hosted by Michael Barbaro. Twenty minutes a day, five days a week, ready by 6 a.m. Unlock full access to New York Times podcasts and explore everything from politics to pop culture. Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. Listen to this podcast in New York Times Audio, our new iOS app for news subscribers. Download now at nytimes.com/audioapp
…
continue reading
Content provided by Audioboom and Not So Different: a Podcast from The Center for Biosimilars. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and Not So Different: a Podcast from The Center for Biosimilars or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
S6 Ep21: Biosimilar Oncology Roundup for November 2023—Podcast Edition
MP3•Episode home
Manage episode 387355791 series 2161808
Content provided by Audioboom and Not So Different: a Podcast from The Center for Biosimilars. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and Not So Different: a Podcast from The Center for Biosimilars or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Show notes
- Webinar: Where Do Biosimilars Fit Into the Cancer Treatment Puzzle?
- Part 1: Oncology Biosimilars Offer Comparable Benefits to Originators at Lower Prices
- Part 2: French Study Finds Trastuzumab Biosimilar Program Could Generate Meaningful Savings
- Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
- Denosumab Biosimilar Demonstrates Positive Safety Results in Chinese Study
- Eye on Pharma: Denosumab Biosimilar Data; COA Forms New Committee; IGBA and WHO Collaborate
- Similar Safety Profiles of Biosimilar, Reference Pegfilgrastim Found in Clinical Studies
- Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone
155 episodes
MP3•Episode home
Manage episode 387355791 series 2161808
Content provided by Audioboom and Not So Different: a Podcast from The Center for Biosimilars. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and Not So Different: a Podcast from The Center for Biosimilars or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Show notes
- Webinar: Where Do Biosimilars Fit Into the Cancer Treatment Puzzle?
- Part 1: Oncology Biosimilars Offer Comparable Benefits to Originators at Lower Prices
- Part 2: French Study Finds Trastuzumab Biosimilar Program Could Generate Meaningful Savings
- Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
- Denosumab Biosimilar Demonstrates Positive Safety Results in Chinese Study
- Eye on Pharma: Denosumab Biosimilar Data; COA Forms New Committee; IGBA and WHO Collaborate
- Similar Safety Profiles of Biosimilar, Reference Pegfilgrastim Found in Clinical Studies
- Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone
155 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.